Published: Oct 12, 2021
Positive high-level results from the TACKLE Phase III COVID-19 treatment trial showed AstraZenecas AZD7442, a long-acting antibody (LAAB) combination, achieved a statistically significant reduction in severe COVID-19 or death compared to placebo in non-hospitalised patients with mild-to-moderate symptomatic COVID-19.
Published: Aug 04, 2021
Chulalongkorn University’s Faculty of Medicine is seeking healthy volunteers for human trials of its ChulaCov19 vaccine in elderly people. To be eligible, volunteers must be 56-75 years old with no underlying disease and never have been infected with Covid-19 or vaccinated.